+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

  • ID: 4770928
  • Report
  • 71 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

Summary

In terms of First-in-Class (FIC) product innovation, the Chronic Obstructive Pulmonary Disease (COPD) pipeline is lagging behind the asthma pipeline. Higher levels of First-in-Class (FIC) innovation in the asthma pipeline are focused on meeting the large unmet need for therapies which can treat severe asthma phenotypes.

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are both highly prevalent, chronic, inflammatory diseases of the airways and lungs. The asthma market is highly saturated with relatively efficacious standard therapies and the Chronic Obstructive Pulmonary Disease (COPD)market is also highly saturated with therapies that help to prevent exacerbations of the disease. However, there is considerable unmet need for innovative new therapies for severe asthmatics who do not respond to the current standards of care, and treatments which can reverse the progression of Chronic Obstructive Pulmonary Disease (COPD).

First-in-Class (FIC) product development in Chronic Obstructive Pulmonary Disease (COPD) constitutes only a small fraction of the pipeline. Of the pipeline products which had a disclosed molecular target, only 31% are FIC products. In contrast, 41% of the asthma pipeline with a disclosed molecular target is a FIC product. Further to this, 66% of the First-in-Class (FIC) products in the Chronic Obstructive Pulmonary Disease (COPD) pipeline are found in the preclinical stage of development with no First-in-Class (FIC) products in Phase III development or later.

The industry average for First-in-Class (FIC) innovation within a disease area is approximately 40%, which means that not only is innovation in the Chronic Obstructive Pulmonary Disease (COPD) pipeline relatively low in comparison to the asthma pipeline, it is also much lower than the industry average. Combined with the lack of late-stage innovation, it is unlikely that any FIC products will be entering the Chronic Obstructive Pulmonary Disease (COPD) market in the near future.

There is a high unmet need for therapies that treat severe asthma and this is reflected in the asthma pipeline. Monoclonal antibodies (mAbs) are the second most common molecule type in the asthma pipeline, indicating high levels of interest in developing targeted biologic therapies for severe phenotypes of asthma. The asthma market is saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs) and inhaled corticosteroids (ICSs). Therefore, the development of targeted biologic therapies for severe phenotypes of asthma is one way that companies can penetrate the asthma market.

The most prevalent molecular target class in the asthma pipeline is cytokines/chemokines and their receptors, which account for 18% of the pipeline. This group itself is diverse, although interleukins (ILs) and IL receptors are by far the most numerous targets among the cytokines, with IL-33, IL-4, IL-5 and IL-17 being targeted most frequently. These ILs are heavily implicated in the inflammatory response, notably for their role in recruiting inflammatory cells such as eosinophils. The specificity of these therapies means they are highly effective in specific, more severe sub-types of asthma patients, such as those characterized by elevated levels of eosinophils.

The report "Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes", assesses First-in-Class (FIC) innovation across the asthma and Chronic Obstructive Pulmonary Disease (COPD) pipelines.

Scope
  • Both the asthma and COPD markets are highly saturated. Which drug classes are used to treat these disorders? How do the drug classes in the market compare with those in the pipelines?
  • There are 266 and 161 pipeline programs in active development for asthma and COPD, respectively. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
  • Which molecular target classes are prominently represented in the first-in-class asthma and COPD pipelines? Which first-in-class targets have been identified as most promising for asthma and COPD, and is there any overlap?
  • Which companies are the key players within the asthma and COPD markets? Who has been involved in the most licensing and co-development deals for asthma and COPD products? Which first-in-class products have prior deal involvement?
Reasons to Buy
  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems, epidemiology, and treatment options for both asthma and COPD.
  • Visualize the composition of the asthma and COPD markets in terms of dominant molecule types and molecular targets. This allows an understanding of any gaps in the current market.
  • Analyze and compare the asthma and COPD pipelines and stratify by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products for each indication have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class asthma and COPD pipeline products that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for asthma and COPD first-in-class products.
Note: Product cover images may vary from those shown
2 of 2
1.1 List of Tables
1.2 List of Figures

2 Asthma and COPD: Executive Summary
2.1 COPD Lagging Behind Asthma in Terms of Innovation
2.2 Innovation in Asthma Pipeline is Focused Towards Targeted Biologic Therapies for Severe Phenotypes of the Disease
2.3 FIC Innovation in COPD Pipeline is Concentrated at the Early Development Stages

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in Asthma and COPD
4.4 Epidemiology for Asthma and COPD
4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between the Market and Pipeline by Molecular Target Class
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target within the Pipeline

6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Asthma
6.3 COPD
6.4 Asthma and COPD

7 Key Players and Deals
7.1 Overview

8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 About the Authors
8.5 About the publisher
8.6 Contact Us
8.7 Disclaimer

1.1 List of Tables
Table 1: Risk Factors for Asthma
Table 2: Risk Factors for COPD
Table 3: Classification of Asthma by Severity
Table 4: GOLD 2017 Assessment of Airflow Limitation in COPD
Table 5: GOLD 2017 Assessment of Symptoms/Risk of Exacerbations in COPD
Table 6: Asthma’s Diagnosed Prevalent Cases (Millions), 2013-2023
Table 7: COPD’s Diagnosed Prevalent Cases (Millions), 2015-2025

1.2 List of Figures
Figure 1: Global Asthma Market by Molecular Target and Molecule Type, 2019
Figure 2: Global COPD Market by Molecular Target and Molecule Type, 2019
Figure 3: Asthma, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 4: COPD, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 5: Asthma, Global, Pipeline by Molecular Target and Stage of Development, 2019
Figure 6: COPD, Global, Pipeline by Molecular Target and Stage of Development, 2019
Figure 7: Asthma, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 8: COPD, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 9: Asthma, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 10: Asthma, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
Figure 11: COPD, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 12: COPD, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
Figure 13: Asthma, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
Figure 14: COPD, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/4770928
Adroll
adroll